Daily Archives: January 7, 2019

DXB Welcomes Billionth Passenger

DUBAI, United Arab Emirates, Jan. 07, 2019 (GLOBE NEWSWIRE) — Following the official announcement earlier today from HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President & Prime Minister of the UAE and Ruler of Dubai, Dubai Airports and representatives from across the aviation sector and the emirate of Dubai gave the airport’s billionth warm welcome to nine-year-old Arjun and his family who arrived this morning from Orlando, Florida on Emirates flight EK220

HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of Dubai Airports, today welcomed the One Billionth customer to Dubai International airport – nine-year-old Arjun Jayaram from Florida.

At a celebration held in DXB earlier today, Arjun along with his mother Ramya, father Venkatesh and thirteen-year-old brother Varun, were personally greeted by HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of Dubai Airports and warmly welcomed on this, their first visit to Dubai. They were also delighted with details of an unforgettable and surprising set of experiences that showcase Dubai’s longstanding reputation for excitement, luxury and modern Arabic hospitality, organised for the next few days of their trip.

At the airport this afternoon, HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of Dubai Airports said; “This landmark billionth passenger achievement is the result of teamwork and collaboration, and special thanks goes out to each and every member of the airport community who have played a role in this journey.”

His Highness continued, “Of course, we would not be in this position if it weren’t for the visionary leadership of HH Sheikh Rashid bin Saeed Al Maktoum and HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President & Prime Minister of the UAE and Ruler of Dubai, both of whom foresaw the development of Dubai into a global centre for trade, tourism and commerce enabled by a fast-growing and world-leading aviation sector with top-flight airport infrastructure.”

The billionth customer is arguably the most significant in a long litany of achievements since the airport first opened in September 30, 1960 with a tiny terminal building and a runway of compacted sand. Today the hub is widely considered a benchmark for its quality infrastructure, passenger and cargo volumes and high service levels despite unrelenting growth. DXB handles an average of 7.5 million customers every month and this year broke its own traffic record thrice with more than 8.3 million customers in a month.

Nothing puts DXB’s growth in perspective more than the fact that the airport took 51 years – from September 30, 1960 to December 31, 2011 – to reach its 500 millionth passenger but clocked the remaining 500 million in just seven years. Over the past 11 years alone Dubai Airports has opened seven major facilities with an investment of almost $12 billion. Five of those have been at DXB including Terminal 3, Concourses A, B, D and the complete refurbishment and expansion of Terminal 2.

To pick the lucky passenger, Dubai Airports used its passenger traffic forecast to narrow down the selection to a specific flight and approached Emirates to make a random selection.

During their stay, Arjun and his family will be visiting some of the top Dubai experiences and treated like superstars all the way. The family will stay at the iconic Atlantis Hotel and dine at the award-winning restaurants there and even spend a day exploring the Aquaventure water park. A visit to the tallest building in the world – the Burj Khalifa – for an access all areas tour, followed by a personal shopping experience at The Dubai Mall. Then a full day with Arabian Adventures exploring the more traditional side of Dubai, around the Al Fahidi Historical neighbourhood and then into the desert for a dune drive and sunset dinner.

Dubai Airports will be posting highlights of the family’s visit across its social media channels in the days to come.

Media Contact
Hannah Burden Hamer, Dubai Airports, Manager – Corporate Communication
Hannah.BurdenHamer@dubaiairports.ae
T: +9714-5044394

Editors Notes

  • Dubai Airports manages the operation and development of both of Dubai’s airports – DXB and DWC.
  • As integrator, Dubai Airports works to balance the interests of all stakeholders to maintain aviation growth, protect operational resilience and ensure that service providers collaborate to provide a safe and secure service and improve the experience of our customers whilst maintaining a sustainable business.
  • DXB is the world’s number one airport in terms of international passenger traffic and number three globally in terms of total passenger traffic as reported by Airports Council International.
  • Dubai Airport’s forecast team used forecasting tools to identify the day, time and flight which carried the one billionth passenger and randomly selected that passenger in conjunction with the operating airline.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b395d073-9473-47d0-b4b7-620230cc56e0

Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301

Ongoing endometrial and colorectal cancer cohorts intended to support BLA submissions

NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that the ongoing multi-center clinical trial of CK-301 has been expanded to enroll patients in three cohorts intended to support requests for accelerated approval and Biologics License Application (BLA) submissions to the U.S. Food and Drug Administration (FDA). These cohorts include:

  • Microsatellite instability-high (MSI-H) endometrial cancer that has progressed following one or two prior anti-cancer therapies;
  • Microsatellite stable (MSS) endometrial cancer that has progressed following one or two prior anti-cancer therapies; and
  • MSI-H or mismatch repair deficient (dMMR) colorectal cancer that has progressed on or after, or been intolerant of, previous treatments, including a fluoropyrimidine- and oxaliplatin- and irinotecan-based chemotherapy.

Each cohort is evaluating a fixed dose of 800 mg CK-301 every two weeks (Q2W). The primary endpoint for each cohort is objective response rate (ORR), and secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The ongoing trial is also enrolling cohorts of patients with non-small cell lung cancer (NSCLC) and cutaneous squamous cell carcinoma.

“We are excited to advance our first immuno-oncology drug candidate, CK-301, into these potentially registration-enabling cohorts, representing a significant milestone in the execution of our strategy to obtain multiple accelerated approvals for our anti-PD-L1 antibody,” said James F. Oliviero, President and Chief Executive Officer of Checkpoint. “We look forward to presenting interim safety and efficacy data from the ongoing clinical trial in the coming months.”

The Phase 1, open-label, multi-center trial is evaluating the safety and tolerability of ascending doses of CK-301 in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers. Following completion of dose escalation in 2018, multiple dose expansion cohorts were initiated. Preliminary data from the ongoing trial suggest that CK-301 is safe and well-tolerated across dose levels ranging from 200 mg to 800 mg administered every two weeks and 1200 mg administered every three weeks, with treatment-related adverse events consistent with marketed anti-PD-1/PD-L1 antibodies.

About CK-301
CK-301 is a fully-human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death Ligand-1 (PD-L1) and blocks the PD-L1 interaction with the Programmed Death Receptor-1 (PD-1) and B7.1 receptors. PD-L1 is an immune-inhibitory checkpoint molecule expressed on epithelial and vascular endothelial cells, as well as by a number of immune cells, and is utilized by tumor cells as an immune escape mechanism. CK-301’s primary mechanism of action is based on the inhibition of the interaction between PD-L1 and its receptors PD-1 and B7.1, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response.

About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation EGFR inhibitor, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts intended to support one or more Biologics License Application submissions. Checkpoint is headquartered in New York City. For more information, visit www.checkpointtx.com.

Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, statements relating to our plans to submit one or more BLAs and seek accelerated approvals for CK-301, any statements relating to our growth strategy and product development programs, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; risks relating to our ability to seek accelerated approvals for our drug candidates; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

Investor Relations Contact:
Jeremy Feffer
Managing Director, LifeSci Advisors, LLC
(212) 915-2568
jeremy@lifesciadvisors.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com

Favored Tech Previews Groundbreaking Electronic Coating Tech at CES19

Patented Technology Makes Cell Phones Virtually Water Proof, Offers Comprehensive Protective Nano Coating for the Latest Electronic Devices

LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) — Favored Tech, a leading provider for the next generation of multi-functional Nano Protection technology for an ever-growing world of electronic devices, today previewed its revolutionary coating technology at CES19. The solution is designed to provide top to bottom, inside out protection for electronic devices including consumer electronics, automotive, drones, surveillance cameras, Internet of Things, Industrial, computers/laptops and more. Favored Tech will be exhibiting at CES in Las Vegas, NV, at Booth No. 43774, Jan. 8 – 11, at the Sands Expo and Convention Center.

“CES is showcasing the most advanced electronic devices in the world and yet, electronic manufacturers are still facing the challenges to protect their products from various environmental factors in terms of effectiveness and cost,” said James Zong, Founder, CEO and President, Favored Tech. “Our coating solution offers a revolutionary approach to coat all functional parts of electronics devices such as charging ports, cameras, earpiece mesh, USB connectors, preassembled devices and the entire devices and at a significantly lower TCO.”

Favored Tech’s solution leverages patented plasma-enhanced chemical vapor deposition chemistry to provide a unique and simple coating solution like no other on the market today. It renders cell phones virtually water proof by organically combining chemical vapor deposition technology with low-temperature plasma technology. The solution is accomplished at just 40-deg C with no environmental impact or associated costs.

Benefits of this pioneering technology include:

  • Highly scalable and flexible. With the same coating machine, it can coat the device inside out, top to bottom, including the motherboard, USB, FPC/Board/Male plug, earpiece mesh, preassembled or entire device.
  • Tailored for different levels and types of protection from water, corrosion, sweat, mold, humidity, and more.
  • Covers all levels of coating protection including water protection from IPX2 – IPX8.
  • Programmable solution offers the highest performance and fastest turnaround on the market today. Rapid coating cycles of just 1-2 hours.
  • Solution has a negligible impact on conductivity, heat dissipation and signal transmission. No expensive masking or demasking required.
  • Negligible environment impact or associated cost.

The Company designs and manufactures all the equipment needed to coat electronic devices or electronic parts. Favored Tech’s patented technology is designed for mass production and the solution is inherently flexible with no need for expensive integration. It can be easily modeled to suit individual electronic company’s processes and manufacturing needs. Solutions range from seamlessly fitting into various manufacturing flows to fully standalone solutions. In addition, Favored Tech creates an offsite solution managed in the labs of Favored Tech. Currently, more than 5 million units globally are coated daily based on Favored Tech’s solution.

About Favored Tech
Founded in Wuxi, China in 2016 and launched in the United States at CES19, Favored Tech delivers the industry’s most advanced level of coating solution for water protection (IPX2-IPX8), humidity protection, anti-corrosion, liquid replant, mold and sweat protection with negligible impact on conductivity, heat dissipation, signal transmission. The Company has more than 40 patents issued and is the recipient of Huawei Award’s Y2018 Excellent Quality Apparatus and Equipment Supplier. The Company is headquartered in Wuxi, China with offices in Shenzhen, China and San Jose, California. www.favoredtech.com.

Contact: Phyllis Guo
+ 1 408 203 4105
media@favoredtech.com

Favored Tech Previews Groundbreaking Electronic Coating Tech at CES19

Patented Technology Makes Cell Phones Virtually Water Proof, Offers Comprehensive Protective Nano Coating for the Latest Electronic Devices

LAS VEGAS, Jan. 07, 2019 (GLOBE NEWSWIRE) — Favored Tech, a leading provider for the next generation of multi-functional Nano Protection technology for an ever-growing world of electronic devices, today previewed its revolutionary coating technology at CES19. The solution is designed to provide top to bottom, inside out protection for electronic devices including consumer electronics, automotive, drones, surveillance cameras, Internet of Things, Industrial, computers/laptops and more. Favored Tech will be exhibiting at CES in Las Vegas, NV, at Booth No. 43774, Jan. 8 – 11, at the Sands Expo and Convention Center.

“CES is showcasing the most advanced electronic devices in the world and yet, electronic manufacturers are still facing the challenges to protect their products from various environmental factors in terms of effectiveness and cost,” said James Zong, Founder, CEO and President, Favored Tech. “Our coating solution offers a revolutionary approach to coat all functional parts of electronics devices such as charging ports, cameras, earpiece mesh, USB connectors, preassembled devices and the entire devices and at a significantly lower TCO.”

Favored Tech’s solution leverages patented plasma-enhanced chemical vapor deposition chemistry to provide a unique and simple coating solution like no other on the market today. It renders cell phones virtually water proof by organically combining chemical vapor deposition technology with low-temperature plasma technology. The solution is accomplished at just 40-deg C with no environmental impact or associated costs.

Benefits of this pioneering technology include:

  • Highly scalable and flexible. With the same coating machine, it can coat the device inside out, top to bottom, including the motherboard, USB, FPC/Board/Male plug, earpiece mesh, preassembled or entire device.
  • Tailored for different levels and types of protection from water, corrosion, sweat, mold, humidity, and more.
  • Covers all levels of coating protection including water protection from IPX2 – IPX8.
  • Programmable solution offers the highest performance and fastest turnaround on the market today. Rapid coating cycles of just 1-2 hours.
  • Solution has a negligible impact on conductivity, heat dissipation and signal transmission. No expensive masking or demasking required.
  • Negligible environment impact or associated cost.

The Company designs and manufactures all the equipment needed to coat electronic devices or electronic parts. Favored Tech’s patented technology is designed for mass production and the solution is inherently flexible with no need for expensive integration. It can be easily modeled to suit individual electronic company’s processes and manufacturing needs. Solutions range from seamlessly fitting into various manufacturing flows to fully standalone solutions. In addition, Favored Tech creates an offsite solution managed in the labs of Favored Tech. Currently, more than 5 million units globally are coated daily based on Favored Tech’s solution.

About Favored Tech
Founded in Wuxi, China in 2016 and launched in the United States at CES19, Favored Tech delivers the industry’s most advanced level of coating solution for water protection (IPX2-IPX8), humidity protection, anti-corrosion, liquid replant, mold and sweat protection with negligible impact on conductivity, heat dissipation, signal transmission. The Company has more than 40 patents issued and is the recipient of Huawei Award’s Y2018 Excellent Quality Apparatus and Equipment Supplier. The Company is headquartered in Wuxi, China with offices in Shenzhen, China and San Jose, California. www.favoredtech.com.

Contact: Phyllis Guo
+ 1 408 203 4105
media@favoredtech.com